Treatment of acute lymphoblastic leukemia in adults

Critical Reviews in Oncology/Hematology

Volumn 81, Issue 1, 2012, Pages 94-102

  Narayanan, Sujata ^a   Shami, Paul J ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

Acute lymphoblastic leukemia; Adolescent young adult; Chemotherapy; Elderly; Transplant; WHO classification

Indexed keywords

ASPARAGINASE; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; IMATINIB; METHOTREXATE; MITOXANTRONE; NELARABINE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER CLASSIFICATION; CANCER RELAPSE; CLINICAL FEATURE; DRUG MEGADOSE; GERIATRIC CARE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEUKEMIA REMISSION; MINIMAL RESIDUAL DISEASE; PHILADELPHIA CHROMOSOME POSITIVE CELL; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

ADULT; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE;

EID: 84855972519     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.01.014     Document Type: Review

References (77)

1. SEER Cancer Statistics Review, 1975-2006 2009, National Cancer Institute, Bethesda, MD, http://seer.cancer.gov/csr/1975_2006/, based on November 2008 SEER data submission, posted to the SEER web site. M.J. Horner, L.A.G. Ries, M. Krapcho (Eds.).
2. Chessells J.M., Harrison G., Richards S.M., et al. Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment. Arch Dis Child 2001, 85(4):321-325.
3. Shaw M.P., Eden O.B., Grace E., Ellis P.M. Acute lymphoblastic leukemia and Klinefelter's syndrome. Pediatr Hematol Oncol 1992, 9(1):81-85.
4. Mertens A.C., Wen W., Davies S.M., et al. Congenital abnormalities in children with acute leukemia: a report from the Children's Cancer Group. J Pediatr 1998, 133(5):617-623.
5. Toledano S.R., Lange B.J. Ataxia-telangiectasia and acute lymphoblastic leukemia. Cancer 1980, 45(7):1675-1678.
6. Spector L.G., Ross J.A., Robison L.L., Bhatia S. Epidemiology and etiology. Childhood leukemias 2006, 48-66. Cambridge University Press. 2nd ed. C.-H. Pui (Ed.).
7. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976, 33(4):451-458.
8. Harris N.L., Jaffe E.S., Diebold J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999, 17(12):3835-3849.
9. Vardiman J.W., Thiele J., Arber D.A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114:937-951.
10. Patel B., Rai L., Buck G., et al. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. Br J Haematol 2010, 148(1):80-89.
11. Hoelzer D., Thiel H., Loffler H., et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988, 71:123-131.
12. Kantarjian H.M., Thomas D., O'Brien S., et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004, 101:2788-2801.
13. Rowe J.M., Buck G., Burnett A.K., et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the International ALL trial: MRC UKALL XII/ECOG E2993. Blood 2005, 106:3760-3767.
14. Le Q.-H., Thomas X., Ecochard R., et al. Initial and late prognostic factors to predict survival in adult acute lymphoblastic leukaemia. Eur J Haematol 2006, 77:471-479.
15. Krzysztof Mrozek, David P., Harper, Peter D., Aplan Cytogenetics and molecular genetics of acute lymphoblastic leukemia. Hematol Oncol Clin N Am 2009, 23:991-1010.
16. van der Velden V.H., Boeckx N., van Wering E.R., van Dongen J.J. Detection of minimal residual disease in acute leukemia. J Biol Regul Homeost Agents 2004, 18(2):146-154.
17. Campana D., Coustan-Smith E. Minimal residual disease studies by flow cytometry in acute leukemia. Acta Haematol 2004, 112(1-2):8-15.
18. Cave H., van der Werff ten Bosch J., Suciu S., et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group. N Engl J Med 1998, 339(9):591-598.
19. Coustan-Smith E., Behm F.G., Sanchez J., et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998, 351(9102):550-554.
20. van Dongen J.J., Seriu T., Panzer-Grumayer E.R., et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998, 352:1731-1738.
21. Bruggemann M., Raff T., Flohr T., et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006, 107(3):1116-1123.
22. Sanchez J., Serrano J., Gomez P., et al. Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation. Br J Haematol 2002, 116(3):686-694.
23. Spinelli O., Peruta B., Tosi M., et al. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica 2007, 92(5):612-618.
24. Scavino H.F., George J.N., Sears D.A. Remission induction in adult acute lymphocytic leukemia. Use of vincristine and prednisone alone. Cancer 1976, 38(2):672-677.
25. Gottlieb A.J., Weinberg V., Ellison R.R., et al. Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by cancer and leukemia group B. Blood 1984, 64(1):267-274.
26. Larson R.A., Dodge R.K., Burns C.P., et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 1995, 85(8):2025-2037.
27. Nagura E., Kimura K., Yamada K., et al. Nation-wide randomized comparative study of doxorubicin, vincristine and prednisolone combination therapy with and without L-asparaginase for adult acute lymphoblastic leukemia. Cancer Chemother Pharmacol 1997, 33(5):359-365.
28. Cuttner J., Mick R., Budman D.R., et al. Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: a CALGB study. Leukemia 1991, 5(5):425-431.
29. Todeschini G., Tecchio C., Meneghini V., et al. Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin. Leukemia 1998, 12(2):144-149.
30. Bassan R., Lerede T., Rambaldi A., Barbui T. Role of anthracyclines in the treatment of adult acute lymphoblastic leukemia. Acta Haematol 1996, 95(3-4):188-192.
31. Weiss M., Maslak P., Feldman E., et al. Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone. J Clin Oncol 1996, 14(9):2480-2485.
32. Weiss M.A., Heffner L., Lamanna N., et al. A randomized trial of cytarabine compared to a standard vincristine/prednisone-based regimen as induction therapy. J Clin Oncol 2005, 23:6516.
33. Annino L., Vegna M.L., Camera A., et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood 2002, 99(3):863-871.
34. Hoelzer D., Thiel E., Ludwig W.D., et al. Follow-up of the first two successive German multicentre trials for adult ALL (01/81 and 02/84). Leukemia 1993, 7(Suppl 2):S130-S134.
35. Hoelzer D., Thiel E., Löffler H., et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 2008, 71(1):123-131.
36. Kantarjian H.M., O'Brien S., Smith T.L., et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000, 18(3):547-561.
37. Mandelli F., Annino L., Rotoli B. The GIMEMA ALL 0183 trial: analysis of 10-year follow-up. GIMEMA Cooperative Group, Italy. Br J Haematol 1996, 92(3):665-672.
38. Linker C.A., Levitt L.J., O'Donnell M., Forman S.J., Ries C.A. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report. Blood 1991, 78(11):2814-2822.
39. Lazarus H.M., Richards S.M., Chopra R., et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood 2006, 108(2):465-472.
40. Childhood ALL Collaborative Group Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised children. Lancet 1996, 347(9018):1783-1788.
41. Thomas X., Boiron J.M., Huguet F., et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004, 22(20):4075-4086.
42. Jamieson C.H., Amylon M.D., Wong R.M., et al. Allogeneic hematopoietic cell transplantation for patients with high-risk acute lymphoblastic leukemia in first or second complete remission using fractionated total-body irradiation and high dose etoposide: a 15-year experience. Exp Hematol 2003, 31:981-986.
43. Goldstone A.H., Richards S.M., Lazarus H.M., et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008, 111(4):1827-1833.
44. Gleissner B., Gökbuget N., Bartram C.R., et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002, 99(5):1536-1543.
45. Schlieben S., Borkhardt A., Reinisch I., et al. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92. Leukemia 1996, 10:957-963.
46. Hoelzer D. Advances in the management of Ph-positive ALL. Clin Adv Hematol Oncol 2006, 4:804-805.
47. Fielding A.K., Rowe J.M., Richards S.M., et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood 2009, 113(19):4489-4496.
48. Laport G.G., Alvarnas J.C., Palmer J.M., et al. Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. Blood 2008, 112(3):903-909.
49. Thomas D.A., Kantarjian H.M., Ravandi F., et al. Long-term follow-up after frontline therapy with the hyper-CVAD and imatinib mesylate regimen in adults with Philadelphia (Ph) positive acute lymphocytic leukemia (ALL) [abstract]. Blood (ASH Annual Meeting Abstracts) 2007, 110(9). [Abstract 10a].
50. Ravandi F., O'Brien S., Thomas D., et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood 2010, 116(12):2070-2077.
51. Harrison C.J. Cytogenentics in paediatric and adolescents acute lymphoblastic leukaemia. Br J Haematol 2009, 144(2):147-156.
52. Boissel N., Auclerc M.-F., Lheritier V., et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003, 21(5):774-780.
53. Stock W., La M., Sanford B., et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood 2008, 112(5):1646-1674.
54. Huguet F., Leguay T., Raffoux E., et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol 2009, 27:911-918.
55. Robak T. Acute lymphoblastic leukaemia in elderly patients: biological characteristics and therapeutic approaches. Drugs Aging 2004, 21(12):779-791.
56. Delannoy A., Ferrant A., Bosly A., et al. Acute lymphoblastic leukemia in the elderly. Eur J Haematol 1990, 45(2):90-93.
57. Ferrari A., Annino L., Crescenzi S., Romani C., Mandelli F. Acute lymphoblastic leukemia in the elderly: results of two different treatment approaches in 49 patients during a 25-year period. Leukemia 1995, 9(10):1643-1647.
58. Späth-Schwalbe E., Heil G., Heimpel H. Acute lymphoblastic leukemia in patients over 59years of age. Experience in a single center over a 10-year period. Ann Hematol 1994, 69(6):291-296.
59. Delannoy A., Sebban C., Cony-Makhoul P., et al. Age-adapted induction treatment of acute lymphoblastic leukemia in the elderly and assessment of maintenance with interferon combined with chemotherapy. A multicentric prospective study in forty patients. French Group for Treatment of Adult Acute Lymphoblastic Leukemia. Leukemia 1997, 11(9):1429-1434.
60. Bassan R., Di Bona E., Lerede T., et al. Age-adapted moderate-dose induction and flexible outpatient postremission therapy for elderly patients with acute lymphoblastic leukemia. Leuk Lymphoma 1996, 22(3-4):295-301.
61. Vignetti M., Fazi P., Cimino G., et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood 2007, 109(9):3676-3678.
62. Ottmann O.G., Wassmann B., Pfeifer H., et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Cancer 2007, 109(10):2068-2076.
63. Chucrallah A.E., Stass S.A., Huh Y.O., Albitar M., Kantarjian H.M. Adult acute lymphoblastic leukemia at relapse. Cytogenetic, immunophenotypic, and molecular changes. Cancer 1995, 76(6):985-991.
64. Guglielmi C., Cordone I., Boecklin F., et al. Immunophenotype of adult and childhood acute lymphoblastic leukemia: changes at first relapse and clinico-prognostic implications. Leukemia 1997, 11(9):1501-1507.
65. Koller C.A., Kantarjian H.M., Thomas D., et al. The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. Leukemia 1997, 11(12):2039-2044.
66. Weiss M.A., Aliff T.B., Tallman M.S., et al. A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia. Cancer 2002, 95(3):581-587.
67. Hiddemann W., Büchner T., Heil G., et al. Treatment of refractory acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM). Leukemia 1990, 4(9):637-640.
68. Kantarjian H.M., Walters R.S., Keating M.J., Barlogie B., McCredie K.B., Freireich E.J. Experience with vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy in adults with refractory acute lymphocytic leukemia. Cancer 1989, 64(1):16-22.
69. Yap B.S., McCredie K.B., Keating M.J., Bodey G.P., Freireich E.J. Asparaginase and methotrexate combination chemotherapy in relapsed acute lymphoblastic leukemia in adults. Cancer Treat Rep 1981, 65(Suppl 1):83-87.
70. Thomas D.A., Kantarjian H., Smith T.L., et al. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer 1999, 86(7):1216-1230.
71. DeAngelo D.J., Yu D., Johnson J.L., et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood 2007, 109(12):5136-5142.
72. Jeha S., Gaynon P.S., Razzouk B.I., et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol 2006, 24(12):1917-1923.
73. Ginaldi L., De Martinis M., Matutes E., et al. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol 1998, 51:364-369.
74. Rytting M., Thomas D., Franklin A., et al. Young adults with acute lymphoblastic leukemia (ALL) treated with adapted augmented Berlin-Frankfurt-Munster (ABFM) therapy [abstract 3957]. Blood 2008, 112.
75. Gokbuget N., Hoelzer D. Rituximab in the treatment of adult ALL. Ann Hematol 2006, 85:117-119.
76. Hoelzer D., Huettmann A., Kaul F., et al. Immunochemotherapy with rituximab in adult CD20 B-precursor ALL improves molecular CR rate and outcome in standard risk (SR) as well as in high risk (HR) patients with SCT [abstract 481]. Haematologica 2009, 94(Suppl 2).
77. Pui C.H., Relling M.V., Downing J.R. Acute lymphoblastic leukemia. N Engl J Med 2004, 350(April (15)):1535-1548.